Site logo
Site logo
<div id="myExtraContent1"> </div>
<div id="myExtraContent5"> </div>

Stacks Image 7897

Stacks Image 90
Stacks Image 92
Stacks Image 94
Stacks Image 96
Stacks Image 98
Stacks Image 100
Stacks Image 102
Stacks Image 104

TIG Nanostructure IgG Complex

Effective therapeutic intervention is increasingly dependent on the early detection of protein biomarkers whose presence reflects the onset or progressive state of a disease. Technically, this requires the high-fidelity detection of protein biomarkers that are often present in very low abundance.

Improved detection and quantification of protein biomarkers are becoming key determinants allowing the early diagnosis and successful treatment of progressive diseases including cancer, diabetes, Alzheimer’s disease, and other neurodegenerative diseases. Quantitative detection of these low-abundance protein biomarkers presents unique technical problems.
Numerous biosensor platforms are being developed to enhance the detection sensitivity of protein biomarkers. Biomarkers can be detected using a variety of native and engineered binding domains. Imiplex’s TriPol binder approach is designed to provide optimal analyte detection efficiency through the formation of multivalent interactions with the analyte and detector molecule.

Many bioanalytical methods rely on antibodies as the means of capturing and detecting a biomarker. Consequently, fidelity of antibody immobilization becomes a key limitation to optimization of biosensor sensitivity and detection reproducibility. One TriPol binder variant, TIG is designed to provide a flexible binder system for antibodies, allowing the rapid development of detector systems for human biomarker identification and pathogen detection.

<div id="myExtraContent7"> </div>
<div id="myExtraContent8"> </div>